Anti-erythropoietin Antibodies Followed by Endogenous Erythropoietin Production in a Dialysis Patient

Overview

Journal Pediatr Nephrol

Specialties Nephrology
Pediatrics

Date 2010 Jan 22

PMID 20091055

Citations 2

Authors

Parnell Mattison

Kiran Upadhyay

Jennifer E Wilcox

Asha Moudgil

Douglas M Silverstein

Affiliations

Soon will be listed here.

Abstract

We present a case of a young girl with end-stage renal disease secondary to anti-glomerular basement membrane disease who was receiving maintenance peritoneal dialysis and developed pure red cell aplasia secondary to anti-erythropoietin (EPO) antibodies. This occurred 13 months after the initiation of EPO alfa therapy for anemia. Initially, the patient required intermittent red blood cell transfusions. After immunosuppressive therapy had been initiated with corticosteroids and cyclosporine, the EPO antibody levels decreased precipitously, associated with an increased level of endogenous EPO production. For the following 6 months, the patient maintained adequate (>10 g/dL) hemoglobin levels and did not require red cell transfusions.

Citing Articles

Management of anemia with erythropoietic-stimulating agents in children with chronic kidney disease.

Warady B, Silverstein D Pediatr Nephrol. 2013; 29(9):1493-505.

PMID: 24005791 DOI: 10.1007/s00467-013-2557-x.

Recovery of native erythropoietin in a patient with erythropoietin-associated pure red cell aplasia.

Prus K, Al-Rahawan M Pediatr Nephrol. 2013; 29(1):161-2.

PMID: 23917451 DOI: 10.1007/s00467-013-2580-y.

References

Bennett C, Cournoyer D, Carson K, Rossert J, Luminari S, Evens A . Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project. Blood. 2005; 106(10):3343-7. PMC: 1895064. DOI: 10.1182/blood-2005-02-0508. View

Casadevall N, Rossert J . Importance of biologic follow-ons: experience with EPO. Best Pract Res Clin Haematol. 2005; 18(3):381-7. DOI: 10.1016/j.beha.2005.01.014. View

Koshy S, Geary D . Anemia in children with chronic kidney disease. Pediatr Nephrol. 2007; 23(2):209-19. PMC: 2668634. DOI: 10.1007/s00467-006-0381-2. View

Evens A, Bennett C, Luminari S . Epoetin-induced pure red-cell aplasia (PRCA): preliminary results from the research on adverse drug events and reports (RADAR) group. Best Pract Res Clin Haematol. 2005; 18(3):481-9. DOI: 10.1016/j.beha.2005.01.017. View

Mason S, La S, Mytych D, Swanson S, Ferbas J . Validation of the BIACORE 3000 platform for detection of antibodies against erythropoietic agents in human serum samples. Curr Med Res Opin. 2003; 19(7):651-9. DOI: 10.1185/030079903125002414. View

Cournoyer D, Toffelmire E, Wells G, Barber D, Barrett B, Delage R . Anti-erythropoietin antibody-mediated pure red cell aplasia after treatment with recombinant erythropoietin products: recommendations for minimization of risk. J Am Soc Nephrol. 2004; 15(10):2728-34. DOI: 10.1097/01.ASN.0000140219.28618.9F. View

Eckardt K, Casadevall N . Pure red-cell aplasia due to anti-erythropoietin antibodies. Nephrol Dial Transplant. 2003; 18(5):865-9. DOI: 10.1093/ndt/gfg182. View

Eschbach J, Kelly M, Haley N, Abels R, Adamson J . Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. N Engl J Med. 1989; 321(3):158-63. DOI: 10.1056/NEJM198907203210305. View

Duffield J, Mann S, Horn L, Winney R . Low-dose cyclosporin therapy for recombinant erythropoietin-induced pure red-cell aplasia. Nephrol Dial Transplant. 2004; 19(2):479-81. DOI: 10.1093/ndt/gfg535. View

10.

Krantz S . Pure red-cell aplasia. N Engl J Med. 1974; 291(7):345-50. DOI: 10.1056/NEJM197408152910707. View

11.

Chng W, Tan L, Liu T . Cyclosporine treatment for patients with CRF who developed pure red blood cell aplasia following EPO therapy. Am J Kidney Dis. 2003; 41(3):692-5. DOI: 10.1053/ajkd.2003.50132. View

12.

Andrade J, Taylor P, Love J, Levin A . Successful reintroduction of a different erythropoiesis-stimulating agent after pure red cell aplasia: relapse after successful therapy with prednisone. Nephrol Dial Transplant. 2005; 20(11):2548-51. DOI: 10.1093/ndt/gfi018. View

13.

Weber G, Gross J, Kromminga A, Eckardt K . Allergic skin and systemic reactions in a patient with pure red cell aplasia and anti-erythropoietin antibodies challenged with different epoetins. J Am Soc Nephrol. 2002; 13(9):2381-3. DOI: 10.1097/01.asn.0000027031.79843.6c. View

14.

Van Regenmortel M . Improving the quality of BIACORE-based affinity measurements. Dev Biol (Basel). 2003; 112:141-51. View

15.

Peces R, de la Torre M, Alcazar R, Urra J . Antibodies against recombinant human erythropoietin in a patient with erythropoietin-resistant anemia. N Engl J Med. 1996; 335(7):523-4. DOI: 10.1056/NEJM199608153350717. View

16.

Schellekens H . Immunologic mechanisms of EPO-associated pure red cell aplasia. Best Pract Res Clin Haematol. 2005; 18(3):473-80. DOI: 10.1016/j.beha.2005.01.016. View

17.

Vartia A, Asola M, Tertti R, Kunelius P, Metsarinne K . Two haemodialysis patients with epoetin alfa-induced pure red-cell aplasia recovered despite treatment with another epoetin preparation. Nephrol Dial Transplant. 2004; 19(5):1313-6. DOI: 10.1093/ndt/gfh089. View

18.

Casadevall N, Dupuy E, Tobelem G, Varet B, Mayeux P . Autoantibodies against erythropoietin in a patient with pure red-cell aplasia. N Engl J Med. 1996; 334(10):630-3. DOI: 10.1056/NEJM199603073341004. View

19.

Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian J, Martin-Dupont P . Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med. 2002; 346(7):469-75. DOI: 10.1056/NEJMoa011931. View

20.

Winearls C, Oliver D, Pippard M, Reid C, Downing M, COTES P . Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet. 1986; 2(8517):1175-8. DOI: 10.1016/s0140-6736(86)92192-6. View